Log In Sign up
The largest database of trusted experimental protocols

Chz868

Manufactured by Novartis
Visit Supplier

CHZ868 is a compact and versatile benchtop centrifuge designed for a wide range of applications in laboratory settings. It features a robust construction, multiple speed settings, and a user-friendly control panel. The core function of CHZ868 is to separate different components of a liquid mixture through centrifugal force, enabling researchers and technicians to efficiently process and prepare samples for further analysis or experimentation.

Automatically generated - may contain errors

Lab products found in correlation

Dimethyl sulfoxide (dmso), by Merck Group (2 mentions) Ruxolitinib, by Chemietek (1 mentions) Cyt387, by Chemietek (1 mentions) Bms911543, by Chemietek (1 mentions) Vincristine, by Cayman Chemical (1 mentions) Cytarabine, by Merck Group (1 mentions) Doxorubicin, by Merck Group (1 mentions) Bbt594, by Novartis (1 mentions) Bsk805, by Novartis (1 mentions) Ruxolitinib, by Selleck Chemicals (1 mentions) Dexamethasone (dex), by Merck Group (1 mentions) Trametinib, by Novartis (1 mentions) Ruxolitinib, by Novartis (1 mentions) Hydroxypropyl β cyclodextrin hpbcd, by Merck Group (1 mentions)

4 protocols using chz868

1

Oral Administration of Novel JAK Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
CHZ868 was synthesized by Novartis and stored at 1mM in DMSO for in vitro use. For in vivo applications, CHZ868 was administered orally at 15 mg/kg twice daily (bid) or at 15, 20, 30 or 40 mg/kg once daily (qd). CYT387, BMS911543 and ruxolitinib were purchased from Chemietek. SAR302503 was synthesized as described(Marubayashi et al., 2010 (link)); these agents were stored at 1mM in DMSO at −20°C.
Meyer S.C., Keller M.D., Chiu S., Koppikar P., Guryanova O.A., Rapaport F., Xu K., Manova K., Pankov D., O’Reilly R.J., Kleppe M., McKenney A.S., Shih A.H., Shank K., Ahn J., Papalexi E., Spitzer B., Socci N., Viale A., Mandon E., Ebel N., Andraos R., Rubert J., Dammassa E., Romanet V., Dölemeyer A., Zender M., Heinlein M., Rampal R., Weinberg R.S., Hoffman R., Sellers W.R., Hofmann F., Murakami M., Baffert F., Gaul C., Radimerski T, & Levine R.L. (2015). CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer cell, 28(1), 15-28.
+ Open protocol
+ Expand
2

Evaluating Targeted Leukemia Therapies

Check if the same lab product or an alternative is used in the 5 most similar protocols
All continuous variables were compared using a two-sided t-test or one-way ANOVA, followed by Dunnett’s test or Tukey’s test for multiple comparisons, and error bars in all figures represent the SEM. Survival curves were compared using the log-rank test with GraphPad software. BSK805, BVB808, BBT594, and CHZ868 were synthesized by Novartis. Dexamethasone, cytarabine, and doxorubicin were purchased from Sigma-Aldrich. Vincristine was purchased from Cayman Chemical. Ruxolitinib was purchased from SelleckChem.
Wu S.C., Li L.S., Kopp N., Montero J., Chapuy B., Yoda A., Christie A.L., Liu H., Christodoulou A., van Bodegom D., van der Zwet J., Layer J.V., Tivey T., Lane A.A., Ryan J.A., Ng S.Y., DeAngelo D.J., Stone R.M., Steensma D., Wadleigh M., Harris M., Mandon E., Ebel N., Andraos R., Romanet V., Dölemeyer A., Sterker D., Zender M., Rodig S.J., Murakami M., Hofmann F., Kuo F., Eck M.J., Silverman L.B., Sallan S.E., Letai A., Baffert F., Vangrevelinghe E., Radimerski T., Gaul C, & Weinstock D.M. (2015). Activity of the type II JAK2 inhibitor CHZ868 in B-cell acute lymphoblastic leukemia. Cancer cell, 28(1), 29-41.
+ Open protocol
+ Expand
3

JAK2 and AXL Inhibition Strategies

Check if the same lab product or an alternative is used in the 5 most similar protocols
JAK2 inhibitors CHZ868, BBT594 (type II), ruxolitinib (type I), and MEK inhibitor trametinib were from Novartis through Material Transfer Agreement; AXL inhibitors bemcentinib and gilteritinib were purchased from BioVision and Sellekchem. CHZ868 was administered by oral gavage at 15 mg/kg every day, bemcentinib at 50 mg/kg twice a day, and trametinib at 0.3 mg/kg every day. Inhibitors for in vitro use were stored at −20°C in DMSO.
Codilupi T., Szybinski J., Arunasalam S., Jungius S., Dunbar A.C., Stivala S., Brkic S., Albrecht C., Vokalova L., Yang J.L., Buczak K., Ghosh N., Passweg J.R., Rovo A., Angelillo-Scherrer A., Pankov D., Dirnhofer S., Levine R.L., Koche R, & Meyer S.C. (2023). Development of Resistance to Type II JAK2 Inhibitors in MPN Depends on AXL Kinase and Is Targetable. Clinical Cancer Research, 30(3), 586-599.
+ Open protocol
+ Expand
4

Ruxolitinib and JQ1 Compound Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Ruxolitinib and CHZ868 were provided by Novartis. (+)-JQ1 (JQ1) and iBET-151 were kindly provided by James Bradner (Dana Farber Cancer Institute, Boston, MA). For in vitro use, compounds were dissolved in dimethylsulfoxide (DMSO) (Sigma-Aldrich) at a final stock concentration of 10 mM (stored at −20°C) and diluted to the appropriate concentration from stock prior to use. For in vivo application, Ruxolitinib was dissolved and administered orally (oral gavage) in 0.5% methylcellulose solution (Sigma-Aldrich) at 90 mg/kg twice daily for the indicated duration. JQ1 was reconstituted in one part DMSO to nine parts 10% (w/v) hydroxypropyl-β-cyclodextrin (HPBCD) (Sigma-Aldrich) solution and administered via intraperitoneal injection at 50 mg/kg once daily for the indicated duration.
Kim S.K., Knight D.A., Jones L.R., Vervoort S., Ng A.P., Seymour J.F., Bradner J.E., Waibel M., Kats L, & Johnstone R.W. (2018). JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias. Genes & Development, 32(11-12), 849-864.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!